SECsense Logo

AstraZeneca PLC 6-K Report: May 2025 Voting Rights Update

$AZN
Form 6-K
Filed on: 2025-05-01
Source
AstraZeneca PLC 6-K Report: May 2025 Voting Rights Update

Here are the key insights extracted from the provided financial report section:

  1. Type of Document: The report is a Form 6-K, which is typically used by foreign companies to report to the SEC.
  2. Company Information:
  • Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
  • Commission File Number: 001-11960.
  1. Reporting Period: The information pertains to the month of May 2025.
  2. Total Voting Rights:
  • As of April 30, 2025, AstraZeneca has issued a total of 1,550,638,452 ordinary shares with voting rights (each share valued at US$0.25).
  • There are no shares held in Treasury.
  • Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,638,452.
  1. Regulatory Compliance:
  • The notification is in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
  • The total number of voting rights is relevant for shareholders to determine whether they need to notify changes in their interest under the UK Financial Conduct Authority's rules.
  1. Company Overview: AstraZeneca is described as a global biopharmaceutical company focusing on prescription medicines in areas such as Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company operates in over 125 countries.
  2. Contact Information: The report includes references to contact details for the Investor Relations Team and Media contacts but does not specify them in the excerpt.
  3. Signature: The report is signed by Adrian Kemp, the Company Secretary, on May 1, 2025.

This summary highlights the essential details regarding AstraZeneca's voting rights and regulatory compliance, providing a clear overview of the company's governance structure as of the specified date.